Wall Street Bullish on HIMS' GLP-1 Pivot, but Regulatory and Margin Risks Keep Thesis in Wait Mode

What happened

Wall Street sentiment has turned more constructive on Hims & Hers, citing the company's strategic pivot to branded GLP-1 drugs and its rapid international expansion as catalysts for a longer-term turnaround. However, the latest DeepValue master report maintains a WAIT rating at $24.20, underscoring that the pivot has inflicted near-term damage: Q1 2026 revenue grew only 4% year-over-year, gross margin plunged to 65% from 73%, and the company swung to a $92 million net loss. Critically, the company faces unresolved regulatory and legal overhangs, including a DOJ referral and being named in an FDA statement on compounded GLP-1 restrictions, which could force further disruptions. While early branded Wegovy shipments exceeded 125,000 in six weeks, management warned of an additional 'couple of points' of gross margin degradation, and Monthly Revenue per Subscriber has already fallen to $80 from $85. In short, the bullish narrative is based on potential, but the current financial and regulatory reality dictates patience until Q2 and Q3 results prove that the pivot can generate sustainable margin and growth.

Implication

The turn in Wall Street sentiment is a positive sign but does not negate the fundamental hurdles the company must clear over the next 6-12 months. The core thesis hinges on Q2 2026 results (forecast $680M-$700M revenue, $35M-$55M adjusted EBITDA) and evidence that branded GLP-1 demand persists beyond the launch quarter. If gross margin stabilizes near 65% and the company avoids new enforcement actions, the stock could re-rate to the base-case $28 value. However, any escalation in DOJ/FDA scrutiny or further margin degradation would likely send the stock toward the bear-case $16. Given the limited margin of safety and the binary nature of regulatory risks, the appropriate stance remains WAIT with an attractive entry at $18 and a re-assessment window of 6-12 months.

Thesis delta

The market narrative has shifted from 'compounded GLP-1 risk' to 'branded GLP-1 opportunity,' but the DeepValue analysis insists that the pivot's cost and legal exposure keep the risk/reward unfavorable at current prices. Until Q2 2026 results validate that the pivot is on track and margins are stabilizing, the thesis remains cautious. The delta is that sentiment has improved, but the fundamentals and risks have not changed enough to upgrade from WAIT.